Inflammation types and molecular causes of allergic bronchopulmonary aspergillosis
Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis
Qianfoshan Hospital · NCT07040332
This project will look for different inflammatory patterns and molecular biomarkers in people with ABPA to see if those patterns link to different clinical outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 140 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Qianfoshan Hospital (other) |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT07040332 on ClinicalTrials.gov |
What this trial studies
This is an observational cohort study enrolling patients who meet diagnostic criteria for allergic bronchopulmonary aspergillosis or fungal‑sensitized asthma. Researchers will collect clinical data and biological samples, including procedures that may involve bronchoscopy, to profile immune and inflammatory molecular signatures. The goal is to define inflammation-based subtypes (precision typing), identify biomarkers that mark those subtypes, and correlate each phenotype with clinical outcomes. The work is conducted by Qianfoshan Hospital in collaboration with Shanghai Pulmonary Hospital, Fudan University, and Guizhou Provincial People's Hospital.
Who should consider this trial
Good fit: Adults who meet diagnostic criteria for ABPA or fungal‑sensitized asthma, are non‑smokers, and can safely undergo bronchoscopy and study procedures are ideal candidates.
Not a fit: People with HIV, active malignancy, blood or autoimmune disorders, prior pulmonary tuberculosis, invasive pulmonary fungal disease, current or past smoking history, or who cannot undergo bronchoscopy are unlikely to benefit from participating.
Why it matters
Potential benefit: If successful, this could allow doctors to classify ABPA by inflammatory subtype and guide more personalized treatment decisions.
How similar studies have performed: Inflammatory phenotyping has produced useful results in broader asthma research, but precise inflammatory subtyping and validated biomarkers specifically for ABPA are relatively novel and less established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Meets the diagnostic criteria for allergic bronchopulmonary aspergillosis. * Meets the diagnostic criteria for fungal-sensitized asthma. Exclusion Criteria: * Human immunodeficiency virus infection. * Malignant tumor. * Blood system disease. * autoimmune system disease. * History of pulmonary tuberculosis. * Patients with a history of smoking or still smoking. * Invasive pulmonary fungal disease. * Contraindications electronic bronchoscopy
Where this trial is running
Jinan, Shandong
- Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China — Jinan, Shandong, China (RECRUITING)
Study contacts
- Study coordinator: Qian Qi, Prof.
- Email: qiqianqlh@163.com
- Phone: +86 13706380314
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Allergic Bronchopulmonary Aspergillosis